Taysha Gene Therapies shares are trading lower after the company announced it will discontinue the development of its TSHA-120 program in evaluation for the treatment of giant axonal neuropathy following feedback from the FDA.
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies has announced that it will discontinue the development of its TSHA-120 program for the treatment of giant axonal neuropathy, following feedback from the FDA. This has led to a decrease in the company's share price.
September 20, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Taysha Gene Therapies' decision to discontinue its TSHA-120 program has led to a decrease in its share price.
The discontinuation of a major program like TSHA-120 is a significant setback for Taysha Gene Therapies. This negative news has directly impacted the company's share price, causing it to drop. The decision was made following feedback from the FDA, indicating regulatory issues which could further affect investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100